Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays

Inclusion Criteria: * Provision of signed or thumb printed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female aged between 18 years and 55 years inclusive. * Resident within the study area * In good general health as evidenced by medical history and clinical examination before entering the study Ability to take oral Coartem and low-dose primaquine anti-malarials upon conclusion of day 2 (2nd direct skin feed) and be willing to adhere to the medication regimen * For females, she must be of non-childbearing potential or use appropriate measures to prevent pregnancy for 30 days after receiving Coartem and primaquine. Non-childbearing potential means she is surgically sterilized or at least one year post-menopausal. Appropriate measures to prevent pregnancy include abstinence or adequate contraceptive precautions (i.e. intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant or Depo-Provera). * For males, he must be willing to ensure that he does not get his partner(s) pregnant for at least 3 months after treatment with primaquine. Appropriate measures to prevent pregnancy include abstinence or adequate contraceptive precautions in either the participant or the partner. * Positive for P. falciparum gametocytes as measured by polymerase chain reaction (PCR) with cycle threshold (cT) value \< 31. Exclusion Criteria: Presence of any signs or symptoms of malaria * Presence of contraindications to administration of Coartem and primaquine as indicated in the respective drug package inserts * History of severe allergic reactions to mosquito bites (other than pruritus and local swelling) * Pregnant (i.e. a positive pregnancy test) * Current or recent (within the preceding 2 weeks) use of antimalarial treatment * Current participation in a malaria vaccine study * Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.